Stratus N-Acetylprocainamide Fluorometric Enzyme I
by American Dade 510(k)
Active
510(k) K853547
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK853547 | Date16 Sep 1985 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Recalls
No FDA recalls on record, checked 5 Oct 2026.
Specification
- 510(k) Number
- FDA Product Code
- LAN
- Device Class
- Class II
- Regulation
- 21 CFR Part 862.3320
- Advisory Committee
- Clinical Toxicology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 1 Oct 2026
The Stratus N-Acetylprocainamide Fluorometric Enzyme I is an enzyme immunoassay device designed for the quantitative measurement of N-acetylprocainamide (NAPA) in biological samples. NAPA is a metabolite of procainamide, a medication used to treat certain heart rhythm disorders, and its levels are monitored to assess drug metabolism and potential toxicity. This device employs fluorometric technology to detect and quantify NAPA concentrations, enabling clinical assessment in toxicology settings.
This device is intended for use in clinical toxicology laboratories and has been cleared by the FDA under 510(k) authorization (K853547). It is classified as a Class II medical device under product code LAN, requiring special controls. The Stratus system operates as a single-use, reagent-based immunoassay, requiring proper storage and handling as specified in the accompanying documentation. No additional regulatory approvals beyond the FDA 510(k) clearance are stated in the provided data.
Other devices from American Dade
Questions
AI-generated answers, 1 Oct 2026
What is the Stratus N-Acetylprocainamide Fluorometric Enzyme I used for?
This device measures N-acetylprocainamide (NAPA) levels in biological samples. NAPA is a metabolite of procainamide, a medication used to treat heart rhythm disorders. Monitoring NAPA helps clinicians assess how the body metabolizes procainamide and detect potential toxicity, ensuring safer drug therapy in toxicology settings.
How is the Stratus N-Acetylprocainamide Fluorometric Enzyme I supplied and used?
The device is supplied as a single-use, reagent-based immunoassay designed for use with the Stratus system. Each assay requires proper handling and storage as outlined in the accompanying documentation. It employs fluorometric technology to detect and quantify NAPA concentrations in clinical laboratory settings.
Is the Stratus N-Acetylprocainamide Fluorometric Enzyme I sterile?
The device is intended for single-use in clinical toxicology laboratories. Sterility is maintained through proper packaging and handling procedures specified in the manufacturer’s instructions to ensure reliable results.
What regulatory approval does the Stratus N-Acetylprocainamide Fluorometric Enzyme I hold?
The device has been cleared by the FDA under 510(k) authorization (K853547) and is classified as a Class II medical device under product code LAN. This clearance confirms its substantial equivalence to a predicate device and compliance with applicable regulatory requirements.
Can this device be reused, or is it designed for single-use only?
The Stratus N-Acetylprocainamide Fluorometric Enzyme I is explicitly designed for single-use. Reuse is not recommended or supported, as it could compromise accuracy, sterility, and regulatory compliance. Each assay must be used once and discarded.